Research programme: CAR-T cell therapy - Fosun Kite Biotechnology
Latest Information Update: 28 Dec 2023
At a glance
- Originator Fosun Kite Biotechnology
- Developer Fosun Kite Biotechnology; Phanes Therapeutics
- Class CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Solid-tumours in China
- 08 Nov 2019 Early research in Solid tumours in China (unspecified route)
- 07 Nov 2019 Fosun Kite and Phanes Therapeutics collaborate for the development and commercialisation of CAR-T cell therapy in China for Solid tumours